BioSpace News Archive

Clovis Oncology, Inc. announced partial results and the partial adjournment of its 2021 Annual Meeting of Stockholders.

Oxurion NV announces that it has received Institutional Review Board approval to initiate a Phase 2 clinical study of THR-687 in patients with Diabetic Macular Edema.

As a project company of Xlife Sciences AG, inflamed pharma GmbH has developed a revolutionary and holistic therapeutic approach to treat both SARS-CoV-2 and flu viruses.

Pfizer Inc. and BioNTech SE announced plans to provide the U.S. government at a not-for-profit price 500 million doses of the companies’ COVID-19 vaccine, 200 million doses in 2021 and 300 million doses in the first half of 2022, to further support the multilateral efforts to address the surge of infection in many parts of the world and to help end the pandemic.

Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced that the ASTONISH Independent Data Monitoring Committee completed the planned safety and efficacy assessment for futility of the company’s ongoing Phase IIB ASTONISH trial in septic shock patients.

MigVax Ltd., a startup company developing an oral subunit vaccine against COVID-19, announced promising results from preclinical tests that demonstrated the effectivity of its MigVax-101 subunit oral vaccine as a booster for previously vaccinated persons.

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, announced participation in the following industry and investor conferences in June.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced the launch of its 6.5mm/7.3mm Slipped Capital Femoral Epiphysis Cannulated Screw system.

Baudax Bio, Inc. announced Gerri Henwood, the Company’s President and Chief Executive Officer, will participate in a fireside chat virtually at the JMP Securities Life Sciences Conference on Thursday, June 17, 2021 at 4:00 p.m. ET.

Oyster Point Pharma, Inc. announced a newly formed research collaboration with Adaptive Phage Therapeutics to leverage APT’s PhageBank™ technology for the development of potential treatments for multiple ophthalmic diseases.